A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
PHASE1Active, not recruitingINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
July 29, 2021
Primary Completion Date
August 1, 2024
Study Completion Date
December 31, 2026
Conditions
Resectable Pancreatic Ductal AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8Stage I Pancreatic Cancer AJCC v8Stage IA Pancreatic Cancer AJCC v8Stage IB Pancreatic Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8